Incyte Medical

Cholangiocarcinoma Europe

MPN Quality Initiatives

Vitiligo Europe

DLBCL Europe

FGFRScience

MPN Connect

Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines.

We are committed to the relentless pursuit of science that can improve the lives of patients.

Our unique expertise in medicinal chemistry and biology has enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across Oncology and Inflammation & AutoImmunity.

Headquartered in Wilmington, Delaware, Incyte has more than 1,700 employees and operations in North America, Europe and Asia.
We are proud to have been recently recognized by Forbes as one of the World’s Most Innovative Companies. Additionally, Incyte has consecutively been named a Top Employer by Science Magazine, placing #2 on the 2020 list.

For more information about Incyte, please visit our corporate website at www.incyte.com and follow us on Twitter: www.twitter.com/incyte. See our Community Guidelines: http://bit.ly/2sV0H5W.


GeneEd

Iconix Biosciences

Agenus

Incyte

Join us at the 42nd Annual J.P. Morgan Healthcare Conference today, where we'll be discussing our pipeline and commitment to pushing the boundaries of scientific innovation. #JPM24 #News https://bit.ly/3tJny43

This weekend, Incyte was involved in the collaboration and discussion of research from the #oncology and #hematology space at the American Society of Hematology Annual Meeting. #SolveOn #ASH23

New research on myeloproliferative neoplasms (MPNs) was shared today at #ASH23. Hear from Patrick Mayes, Vice President of Biotherapeutic Research at Incyte, on what this may mean for the MPN community.

Peter Langmuir, Group Vice President, Oncology Targeted Therapeutics at Incyte, shares thoughts on the AGAVE-201 trial for patients with refractory chronic graft-versus-host disease (GVHD). #ASH23

Domain Not Resolving

DNSSEC

Amazon

LetsEncrypt

Mobile Non Scaleable Content

nginx

Cloudflare CDN

IPv6

Cloudflare Hosting

Person Schema

Agnes Gouesse

Engineering

Aziz Nazha

EVP, Chief Financial Officer

Christiana Stamoulis

Principal Investigator, Pre-Clinical Pharmacology

Hamza Celik

Chairman and CEO

Herve Hoppenot

VP and Chief Compliance Officer

Jill Dailey

Chief Business Officer

John Keller

Executive Vice President, General Counsel and Corporate Secretary

Maria Pasquale

Associate Vice President - Chief Information Security Officer

Nari Narayanan

Chief Medical Officer

Steven H. Stein

Wendy Dixon

Jean-Jacques Bienaime

Edmund P. Harrigan

Julian Baker

Susan Snodgrass

Vice President

Elizabeth Oubre

Director, Marketing Operations

Evan Cimino

Research Scientist

Jim Lee

Group Vice President, Head Inflammation and AutoImmunity Group

Nathalie Mueller-Andriamboavonjy

Senior Manager, Regulatory Affairs Operations

Tera Farhat

Recruiting Consultat Incyte

Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.

Iconix Biosciences provides a toxicogenomics database of microarray and pharmacology data with the expertise to interpret it.

GeneEd is the leading provider of e-Learning solutions for life science, combining advanced web technologies, creative design.

Medical Public Companies With More Than $100M in Revenue

Delaware Companies With Fewer Than 1000 Employees

Southern US Companies With More Than $500 in Revenue

Medical Public Companies With More Than $1B in Revenue

Incyte is a drug discovery and development company which hopes to build a proprietary product pipeline of novel small molecule drugs. Incyte's product pipeline is currently focused on oncology and inflammation and includes compounds in various stages of development. Through partnerships with [Novartis](/organization/novartis), [Eli Lilly](/organization/eli-lilly), and [Pfizer](/organization/pfizer), Incyte intends to promote the clinical development and global commercialization of several of their compounds.

Wilmington

Delaware

United States

North America

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting

Incyte Announces Updated Presentation Time for Upcoming Investor Conference

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte to Report Third Quarter Financial Results

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Incyte announced results from Phase 3 POD1UM-303/InterAACT2 trial

Incyte plans label expansion for cancer drug Monjuvi following positive topline data

Incyte builds GvHD presence with Niktimvo approval

The Netherlands

Europe

Switzerland

India

Asia

United Kingdom

HTML5

Google Drive

Wordpress

Google Analytics

Office 365

Bootstrap

jQuery

DigiCert

Apache Server

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

news impact assignment basic	general
public peers	general
news daily refresh	general	Dec 4, 2024 2:16 PM	ae6e9c26
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	1ac4a15f
crunchbase profile	general	Nov 27, 2024 1:21 PM	09a8beb4
li profile	general	Feb 6, 2024 4:55 PM	54aeadd7
translate crunchbase fundingrounds	general	Nov 28, 2024 2:25 PM	a54bb29a
peers	general	Feb 6, 2024 4:55 PM	10907e4b
news basic	general	Dec 4, 2024 2:13 PM	7a19b80e
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:INCYTE

Incyte Corporation

Last Close

70.39

22/11 21:00

Market Cap

13.66B

Beta: -

Volume Today

1.52M

Avg: -